Richard Laforest1,2, Suzanne E Lapi3,4, Reiko Oyama3, Ron Bose4,5, Adel Tabchy5, Bernadette V Marquez-Nostra3, Jennifer Burkemper3, Brian D Wright3, Jennifer Frye6, Sarah Frye6, Barry A Siegel4,6, Farrokh Dehdashti4,6. 1. Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA. laforestr@wustl.edu. 2. The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. laforestr@wustl.edu. 3. Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA. 4. The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. 5. Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. 6. Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Abstract
PURPOSE: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. PROCEDURES: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. RESULTS: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. CONCLUSION: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
PURPOSE: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. PROCEDURES: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. RESULTS: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. CONCLUSION: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
Entities:
Keywords:
Dosimetry; HER2; PET imaging; Trastuzumab; Zirconium-89
Authors: Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen Journal: Nat Protoc Date: 2010-03-25 Impact factor: 13.491
Authors: Gail H Vance; Todd S Barry; Kenneth J Bloom; Patrick L Fitzgibbons; David G Hicks; Robert B Jenkins; Diane L Persons; Raymond R Tubbs; M Elizabeth H Hammond Journal: Arch Pathol Lab Med Date: 2009-04 Impact factor: 5.534
Authors: Pia Wülfing; Julia Borchard; Horst Buerger; Stefan Heidl; Kurt S Zänker; Ludwig Kiesel; Burkhard Brandt Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Joseph A O'Donoghue; Jason S Lewis; Neeta Pandit-Taskar; Stephen E Fleming; Heiko Schöder; Steven M Larson; Volkan Beylergil; Shutian Ruan; Serge K Lyashchenko; Pat B Zanzonico; Wolfgang A Weber; Jorge A Carrasquillo; Yelena Y Janjigian Journal: J Nucl Med Date: 2017-06-21 Impact factor: 10.057
Authors: Joanne E Mortimer; James R Bading; Jinha M Park; Paul H Frankel; Mary I Carroll; Tri T Tran; Erasmus K Poku; Russell C Rockne; Andrew A Raubitschek; John E Shively; David M Colcher Journal: J Nucl Med Date: 2017-06-21 Impact factor: 10.057
Authors: Adriana V F Massicano; Supum Lee; Bryant K Crenshaw; Tolulope A Aweda; Retta El Sayed; Ian Super; Ron Bose; Bernadette V Marquez-Nostra; Suzanne E Lapi Journal: Cancer Biother Radiopharm Date: 2019-01-24 Impact factor: 3.099
Authors: Feng Chen; Kai Ma; Li Zhang; Brian Madajewski; Pat Zanzonico; Sonia Sequeira; Mithat Gonen; Ulrich Wiesner; Michelle S Bradbury Journal: Chem Mater Date: 2017-09-06 Impact factor: 9.811
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren Journal: Radiology Date: 2020-04-07 Impact factor: 11.105
Authors: Yingbing Wang; Karen L Ayres; Debra A Goldman; Maura N Dickler; Aditya Bardia; Ingrid A Mayer; Eric Winer; Jill Fredrickson; Carlos L Arteaga; José Baselga; Henry C Manning; Umar Mahmood; Gary A Ulaner Journal: Clin Cancer Res Date: 2016-12-23 Impact factor: 12.531
Authors: Farrokh Dehdashti; Ningying Wu; Ron Bose; Michael J Naughton; Cynthia X Ma; Bernadette V Marquez-Nostra; Philipp Diebolder; Cedric Mpoy; Buck E Rogers; Suzanne E Lapi; Richard Laforest; Barry A Siegel Journal: Breast Cancer Res Treat Date: 2018-02-13 Impact factor: 4.872
Authors: Wojciech G Lesniak; Samit Chatterjee; Matthew Gabrielson; Ala Lisok; Bryan Wharram; Martin G Pomper; Sridhar Nimmagadda Journal: Bioconjug Chem Date: 2016-08-09 Impact factor: 4.774